unknown
Stage
2
Investors
About
Axalbion is a clinical-stage pharmaceutical company developing TRPM8 agonists for the treatment of chronic cough and dry eyes, two chronic, common and debilitating disorders, with limited treatment options.
Explore Axalbion's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.